Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Delivery

Background:

• Classical platinum(II) anticancer agents face challenges including systemic toxicity and drug resistance.
• Low bioavailability and lack of tumor selectivity limit the effectiveness of platinum(II) drugs.
• Platinum(IV) prodrugs present advantages like enhanced stability, solubility, and potential for oral administration.

Purpose of the Study:

• To review targeting and delivery strategies for platinum(IV) complexes in cancer treatment.
• To explore methods for improving the efficacy of platinum-based anticancer drugs.
• To summarize recent advancements in platinum(IV) targeted delivery.

Main Methods:

• Review of recent scientific literature on platinum(IV) targeted delivery strategies.
• Categorization of targeting approaches into active and passive strategies.
• Analysis of methods combining platinum(IV) complexes with tumor-targeting moieties.

Main Results:

• Platinum(IV) complexes demonstrate superior stability and bioavailability over platinum(II) drugs.
• Targeted delivery of platinum(IV) complexes can mitigate side effects like non-specific distribution.
• Combination of platinum(IV) with targeting groups offers a promising avenue for novel cancer therapies.

Conclusions:

• Platinum(IV) prodrugs with targeted delivery represent a significant advancement in anticancer drug development.
• Targeted strategies can overcome limitations of traditional platinum-based chemotherapy.
• Further research in this area holds potential for developing more effective and safer cancer treatments.